Answers are grounded in this paper and cite their sources.
Open-label extension study reports on the safety of givinostat in patients with Duchenne muscular dystrophy, suggesting potential for extended usage.
Background/Purpose: Givinostat, an oral histone deacetylase inhibitor, has been investigated for Duchenne muscular dystrophy (DMD) treatment in patients aged ≥6 years. Safety data from the ongoing long-term study of givinostat were evaluated (NCT03373968).
No takes yet. Share an insight, caveat, or question.
Gilling et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: